Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-target...
Q2 2026
Aug 11, 2026
Q1 2026
May 13, 2026
FY 2025
Feb 26, 2026
Q4 2025
Q3 2025
Nov 13, 2025
